US 12,202,823 B2
1,3,4-oxadiazole derivatives as histone deacetylase inhibitors
Yosu Ion Vara Salazar, Guipuzcoa (ES); Eneko Aldaba Arévalo, Guipuzcoa (ES); Tamara Bello Iglesias, Guipuzcoa (ES); Richard Spurring Roberts, Santiago de Compostela (ES); Laureano Simón Buela, Guipuzcoa (ES); José Manuel Brea, Santiago de Compostela (ES); Ángel Carracedo, Santiago de Compostela (ES); and María Isabel Loza García, Santiago de Compostela (ES)
Assigned to QUIMATRYX, S.L., Guipuzcoa (ES); and FUNDACIÓN KERTOR, Santiago de Compostela (ES)
Appl. No. 17/604,017
Filed by QUIMATRYX, S.L., Guipuzcoa (ES); and FUNDACIÓN KERTOR, Santiago de Compostela (ES)
PCT Filed Apr. 16, 2020, PCT No. PCT/EP2020/060695
§ 371(c)(1), (2) Date Oct. 15, 2021,
PCT Pub. No. WO2020/212479, PCT Pub. Date Oct. 22, 2020.
Claims priority of application No. 19382306 (EP), filed on Apr. 17, 2019.
Prior Publication US 2022/0213084 A1, Jul. 7, 2022
Int. Cl. C07D 413/14 (2006.01); C07D 413/10 (2006.01); C07D 471/04 (2006.01); C07D 491/107 (2006.01)
CPC C07D 413/14 (2013.01) [C07D 413/10 (2013.01); C07D 471/04 (2013.01); C07D 491/107 (2013.01)] 15 Claims
 
1. A compound of formula (I)

OG Complex Work Unit Chemistry
or a salt, solvate, stereoisomer or prodrug thereof,
wherein
one or two of W, X, Y or Z is N, and the remainder of W, X, Y and Z are each CH; or each of W, X, Y and Z is CH;
R1 is H; unsubstituted or substituted alkyl; or halogen; and
R2 is an unsubstituted or substituted, aromatic or non-aromatic heterocyclic ring, wherein the ring comprises from 1 to 4 nitrogen atoms, and wherein it is one of these ring nitrogen atoms of the R2 group that forms the bond to the rest of formula (I).